Jyske Bank
Earnings per share outlook for 2025 raised to DKK 77-84
Earnings per share outlook for 2025 raised to DKK 77-84
Jyske Bank expects a net profit of DKK 4.9bn-5.3bn in 2025, corresponding to earnings per share of DKK 77-84. Previously, expectations were for a net profit at the upper end of DKK 3.8bn-4.6bn, corresponding to earnings per share at the upper end of DKK 60-73.
Net profit amounted to DKK 3,992m in Q1-Q3 2025.
The improved outlook is driven by a broadly based positive development. We have seen the effects of favorable financial markets combined with continued solid credit quality, a high level of activity particularly in asset management, and customer growth in prioritized segments.
| Core profit and net profit for the period (DKKm) | Q1-3 2025 | Q1-3 2024 | Index 25/24 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
| Net interest income | 6,629 | 7,275 | 91 | 2,187 | 2,204 | 2,238 | 2,269 | 2,356 |
| Net fee and commission income | 2,073 | 1,836 | 113 | 689 | 658 | 726 | 902 | 627 |
| Value adjustments | 956 | 891 | 107 | 511 | 263 | 182 | 172 | 453 |
| Other income | 202 | 168 | 120 | 33 | 118 | 51 | 12 | 11 |
| Income from operating lease (net) | 82 | 137 | 60 | 19 | 31 | 32 | 31 | 32 |
| Core income | 9,942 | 10,307 | 96 | 3,439 | 3,274 | 3,229 | 3,386 | 3,479 |
| Core expenses | 4,732 | 4,768 | 99 | 1,537 | 1,662 | 1,533 | 1,634 | 1,608 |
| Core profit before loan impairment charges | 5,210 | 5,539 | 94 | 1,902 | 1,612 | 1,696 | 1,752 | 1,871 |
| Loan impairment charges | -22 | 13 | - | 25 | -113 | 66 | 8 | -82 |
| Core profit | 5,232 | 5,526 | 95 | 1,877 | 1,725 | 1,630 | 1,744 | 1,953 |
| Investment portfolio earnings | 127 | 19 | 668 | 52 | 7 | 68 | -33 | 6 |
| Pre-tax profit before non-recurring items | 5,359 | 5,545 | 97 | 1,929 | 1,732 | 1,698 | 1,711 | 1,959 |
| Non-recurring items, Handelsbanken DK/PFA Bank | 0 | -73 | 0 | 0 | 0 | 0 | -18 | -33 |
| Pre-tax profit | 5,359 | 5,472 | 98 | 1,929 | 1,732 | 1,698 | 1,693 | 1,926 |
| Tax | 1,367 | 1,428 | 96 | 474 | 451 | 442 | 425 | 505 |
| Net profit for the period | 3,992 | 4,044 | 99 | 1,455 | 1,281 | 1,256 | 1,268 | 1,421 |
| Interest expense on additional tier 1 capital, recognised on equity | 198 | 195 | 102 | 67 | 66 | 65 | 66 | 66 |
| Summary of balance sheet, end of period (DKKbn) | ||||||||
| Loans and advances | 572.9 | 557.7 | 103 | 572.9 | 574.3 | 566.9 | 567.2 | 557.7 |
| - of which mortgage loans | 375.9 | 361.2 | 104 | 375.9 | 372.2 | 366.7 | 365.8 | 361.2 |
| - of which bank loans | 140.4 | 143.6 | 98 | 140.4 | 141.6 | 144.7 | 144.7 | 143.6 |
| - of which repo loans | 56.6 | 52.9 | 107 | 56.6 | 60.5 | 55.5 | 56.7 | 52.9 |
| Bonds and shares, etc. | 114.7 | 104.3 | 110 | 114.7 | 110.8 | 109.0 | 98.7 | 104.3 |
| Total assets | 745.1 | 765.2 | 97 | 745.1 | 766.8 | 782.3 | 750.2 | 765.2 |
| Deposits | 201.3 | 209.4 | 96 | 201.3 | 197.1 | 198.5 | 198.9 | 209.4 |
| - of which bank deposits | 190.5 | 196.0 | 97 | 190.5 | 189.7 | 191.1 | 190.2 | 196.0 |
| - of which repo and triparty deposits | 10.8 | 13.4 | 81 | 10.8 | 7.4 | 7.4 | 8.7 | 13.4 |
| Issued bonds at fair value | 368.9 | 360.9 | 102 | 368.9 | 368.4 | 368.4 | 362.2 | 360.9 |
| Issued bonds at amortised cost | 53.2 | 77.4 | 69 | 53.2 | 64.0 | 65.9 | 66.6 | 77.4 |
| Subordinated debt | 11.4 | 7.7 | 148 | 11.4 | 7.7 | 7.7 | 7.6 | 7.7 |
| Holders of AT1 capital | 4.9 | 4.9 | 100 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 |
| Shareholders' equity | 46.7 | 44.5 | 105 | 46.7 | 46.0 | 45.3 | 45.7 | 44.5 |
Jyske Bank's Interim Financial Report for Q1-Q3 2025 is expected to be published on 29 October 2025.
Yours faithfully,
Jyske Bank
Contact: Birger Krøgh Nielsen, CFO, tel. +45 89 89 64 44.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Aspire Academy9.10.2025 20:31:58 CEST | Press release
Sir Gareth Southgate, Alessandro Nesta, Rafa Benitez, Carli Lloyd and Ron Jaworski Headline the 11th Aspire Academy Global Summit 2025 in Philadelphia, USA
Karolinska Development AB (publ)9.10.2025 19:24:39 CEST | Press release
Karolinska Development's portfolio company PharmNovo receives approval to initiate a phase 2a trial of its drug candidate PN6047 in Spain
Smith & Nephew UK Ltd9.10.2025 18:30:00 CEST | Press release
Smith+Nephew announces new category I CPT® code for its CARTIHEAL™ AGILI-C™ Cartilage Repair Implant
Coloplast A/S9.10.2025 17:52:12 CEST | Press release
Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting
Coloplast A/S9.10.2025 17:52:12 CEST | Pressemeddelelse
Coloplast interim CEO Lars Rasmussen udtræder af bestyrelsen ved den kommende ordinære generalforsamling
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom